<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001250'>Seizures</z:hpo> and <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drugs (AEDs) affect sleep macroarchitecture and may produce <z:hpo ids='HP_0002189'>excessive daytime sleepiness</z:hpo> (EDS) in patients with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Sleep is a potent activator of <z:hpo ids='HP_0001250'>seizures</z:hpo> and epileptiform discharges </plain></SENT>
<SENT sid="2" pm="."><plain>In some patients, <z:hpo ids='HP_0001250'>seizures</z:hpo> occur exclusively or predominately in sleep </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0270847" disease_type="Disease or Syndrome" abbrv="">Benign focal epilepsy of childhood</z:e> with centrotemporal spikes (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BECTS</z:e>), supplementary sensorimotor area <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> (SSMA) and <z:e sem="disease" ids="C0238111" disease_type="Disease or Syndrome" abbrv="">Lennox Gastaut syndrome</z:e> are a few of the more common <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> syndromes characterized by nocturnal <z:hpo ids='HP_0001250'>seizures</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0002189'>Excessive daytime sleepiness</z:hpo> is a common complaint of patients with <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Causes of EDS include <z:hpo ids='HP_0001250'>seizures</z:hpo>, AEDs, poor sleep hygiene, and coexisting <z:e sem="disease" ids="C0851578,C0852564" disease_type="Disease or Syndrome;Mental or Behavioral Dysfunction" abbrv="">sleep disorders</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Pharmacologic therapy is aimed at identifying the single most effective drug for a given <z:hpo ids='HP_0001250'>seizure</z:hpo> type or <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> syndrome </plain></SENT>
<SENT sid="7" pm="."><plain>Polytherapy is associated with a higher likelihood of adverse effects--most notably, EDS </plain></SENT>
<SENT sid="8" pm="."><plain>Poor sleep hygiene leads to sleep fragmentation that can exacerbate <z:hpo ids='HP_0001250'>seizures</z:hpo> and EDS </plain></SENT>
<SENT sid="9" pm="."><plain>Primary <z:e sem="disease" ids="C0851578,C0852564" disease_type="Disease or Syndrome;Mental or Behavioral Dysfunction" abbrv="">sleep disorders</z:e> should be suspected in patients with EDS, particularly those treated with monotherapy at low serum drug concentrations and well controlled <z:hpo ids='HP_0001250'>seizures</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Treatment of <z:e sem="disease" ids="C0851578,C0852564" disease_type="Disease or Syndrome;Mental or Behavioral Dysfunction" abbrv="">sleep disorders</z:e> may lead to better <z:hpo ids='HP_0001250'>seizure</z:hpo> control </plain></SENT>
</text></document>